Geron Corp
NASDAQ:GERN

Watchlist Manager
Geron Corp Logo
Geron Corp
NASDAQ:GERN
Watchlist
Price: 1.135 USD -1.3% Market Closed
Market Cap: 722.9m USD

EV/EBIT
Enterprise Value to EBIT

-3.3
Current
-5.8
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.3
=
Enterprise Value
444.8m USD
/
EBIT
-136m USD
Market Cap EV/EBIT
US
Geron Corp
NASDAQ:GERN
722.9m USD -3.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -195 781.6
US
Abbvie Inc
NYSE:ABBV
337.7B USD 22.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
163.2B USD 24.2
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 27.2
US
Epizyme Inc
F:EPE
94.1B EUR -555.3
AU
CSL Ltd
ASX:CSL
132.5B AUD 24
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD 13.5
US
Seagen Inc
F:SGT
39.3B EUR -59
EBIT Growth EV/EBIT to Growth
US
Geron Corp
NASDAQ:GERN
Average EV/EBIT: 21
Negative Multiple: -3.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 781.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.2
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -555.3 N/A N/A
AU
CSL Ltd
ASX:CSL
24
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-5.6
2-Years Forward
EV/EBIT
-37.5
3-Years Forward
EV/EBIT
3.1